Independent Financial Group LLC Invests $1.54 Million in Abbott Laboratories $ABT

Key Points

• Independent Financial Group LLC initiated a new position in Abbott Laboratories, buying 15,046 shares worth about $1.54 million in the first quarter.
• Abbott reported strong second-quarter results, topping earnings expectations and raising its full-year 2026 adjusted EPS guidance to $5.45-$5.60.
• Analysts and insiders have turned more positive on the stock, with several firms lifting price targets and Abbott’s CFO and a director recently making share purchases.

Independent Financial Group LLC bought a new stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The fund bought 15,046 shares of the healthcare product maker's stock, valued at approximately $1,545,000.

Other hedge funds have also recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Abound Financial LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at $26,000. Institutional investors and hedge funds own 75.18% of the company's stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares of the company's stock, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Daniel J. Starks purchased 10,000 shares of the business's stock in a transaction dated Monday, April 27th. The stock was bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Evercore dropped their price objective on Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. BTIG Research upped their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a report on Friday. Leerink Partners dropped their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a research report on Tuesday, April 21st. TD Cowen reissued a "buy" rating and set a $115.00 price target on shares of Abbott Laboratories in a report on Friday. Finally, Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research note on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $118.61.

Abbott Laboratories Stock Up 0.0%

Shares of ABT opened at $100.71 on Monday. The business's fifty day moving average price is $89.89 and its two-hundred day moving average price is $102.01. The firm has a market capitalization of $175.41 billion, a price-to-earnings ratio of 32.59, a PEG ratio of 1.73 and a beta of 0.61. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm's quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.